81.16USD-1.54%Mkt Cap: 6.12B USDP/E: —Last update: 2026-05-22
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other infla…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap6.12B USD
Enterprise Value5.13B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-255.84M USD
Revenue/Share—
Last Price81.16 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees261
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.80
PEG—
EV/EBITDA-16.88
EV/Revenue—
P/S—
P/B4.89
EPS (TTM)-4.33
EPS (Forward)-5.22
52W Range
34.3477% of range95.32
52W High95.32 USD
52W Low34.34 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-28.30%
ROA-27.30%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-227.45M USD
CapEx (TTM)5.15M USD
FCF Margin—
FCF Yield-2.33%
Net Debt-1.05B USD
Net Debt/EBITDA3.46
Balance Sheet
Debt/Equity0.01
Current Ratio32.59
Quick Ratio32.38
Book Value/Sh16.87 USD
Cash/Share14.14 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)119.69 USD
Target Range82.00 USD – 160.00 USD
# Analysts16
Ownership
Shares Out.61.90M
Float57.84M
Insiders9.68%
Institutions131.04%
Short Interest
Short Ratio13.6d
Short % Float19.86%
Short % Out.12.60%
Shares Short9.49M
Short (prev mo.)9.73M
Technical
SMA 5081.88 (-0.9%)
SMA 20064.87 (+25.1%)
Beta0.69
S&P 52W Chg28.31%
Avg Vol (30d)628.04K
Avg Vol (10d)720.30K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—